Share Facebook Twitter LinkedIn Pinterest Email Decisions were “finely balanced” and, with hindsight, might have been different, Fiona Scolding KC says.
FibroBiologics advances bone marrow organoid platform for cancer and immune therapiesSeptember 12, 2025